Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza”. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology.Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals:OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience. Jose Manuel Bravo-San Pedro is currently a researcher at the Department of Physiology of the Complutense University of Madrid thanks to a Ramon y Cajal contract grant. He got his Ph.D. in biochemistry, cellular biology and genetics from the University of Extremadura (Caceres, Spain) in 2011, and he did a post-doctoral stage in the laboratory of Prof. Guido Kroemer. His main research interests have always been linked to autophagy, addressing this cellular process associated with neurodegenerative diseases or cancer and recently obesity and specifically related to problems in the correct functioning of the cilium. He is co-inventor of two patents and co-author of 110 publications indexed in PubMed in prestigious international journals, with h-index 45 and 23768 cites (Dec 2022). Fernando Aranda holds a BSc in Biology (2006) and Biochemistry (2007) from the University of Navarra. Then, he specialized in different strategies of Cancer Immunotherapy with a MSc in Biomedical Research (2008), and a PhD Degree (2012) from the University of Navarra (Pamplona) – Cima University of Navarra. More than 12 years in translational research focus on antitumor immune responses and Cancer Immunotherapy. Author of 64 publications indexed in PubMed in prestigious international journals, with h-index 30 and 4,296 cites (October 2022). He completed the Program of Sara Borrell (ISCIII) -competitive Postdoctoral contract- in the Group of Immune Receptors of the Innate and Adaptive System (IDIBAPS), Barcelona (2016-2018). Co-author of 1 invention patent: Composition based on the fibronectin domain A for the treatment of melanoma - WO/2011/101332. In 2012, Fernando Aranda obtained a Scientific Award, "Profesor Durantez" II Edición, for the best scientific article in Tumor Immunology by Fundación LAIR. Recently, Fernando Aranda awarded a competitive Research Fellow contract “Miguel Servet tipo I” by Instituto de Salud Carlos III, to continue his independent researcher career (IP) in cancer immunotherapy issues. Specifically, he is involved in Translational Immunotherapy of Peritoneal Carcinomatosis. Currently, Fernando Aranda leads a research group in cooperation with Dr. Pedro Berraondo.

• 1. Establishment single lung tumors through orthotopic injection Beñat Picabea, Céline Clémenson, Mirari Echepare, Cristina Viu-Idocin, Ane Álava, Estefanía Rodríguez, Michele Mondini, Karmele Valencia 2. Intracardiac injection as a metastatic model in lung cancerEstablishment single lung tumors through orthotopic injection Mirari Echepare, Beñat Picabea, Cristina Viu-Idocin, Ane Álava, Estefanía Rodríguez, Karmele Valencia 3. Adeno-associated viral vector administration to the inner ear and phenotype evaluation in a mouse model of hearing loss Sergio Isola and Carmen Unzu 4. DiLiCre2.0 mouse model: An advanced genome-editing tool to induce mutagenesis in vivo with high spatio-temporal resolution Miguel Vizosoa 5. A new inducible mouse model of FH loss Vincent Zecchini, Chrysanthi Moschandrea, Farina Schneider, and Christian Frezza 6. Monitoring neuronal mitophagy and locomotion deficits in a C. elegans model of Alzheimer's disease Giorgos Garcia Niforos, Eleni Tsakiri, and Konstantinos Palikaras 7. Experimental models and methods for infected wound modeling with Staphylococcus aureus Estela Pérez, Guillermo Landa, Isabel Bescós, Ignacio Ochoa, and Elena Tapia 8. Multiplex immunohistochemistry (IHC) profiling of murine tumour-infiltrating T cells Erminia Romano, Caron Behan, Alexander Baker, Garry Ashton, and Jamie Honeychurch 9. Isolation of Regulatory T Cells from Healthy Murine Mammary Glands D.Michael Mann, Hossein Ehsanbakhsh, and Paula D. Bos 10. Metastasis mouse model of breast cancer derived from Circulating Tumor Cells (CTCs) after primary orthotopic tumor resection. Angela Pérez-Cervera, Haritz Moreno, Helena Villanueva, Angelina Zheleva, Beatriz Moreno, Fernando Lecanda, Fernando Pastor 11. Establishment of humanized patient-derived xenografts (PDXs) from primary human colorectal cancer tumors Carmen Navarrete-Sirvent, Aurora Rivas-Crespo, María Teresa Sánchez-Montero, Alejandra Díaz-Chacón, Regina Peña-Enríquez, Enrique Aranda, Antonio Rodríguez-Ariza, and Silvia Guil-Luna Modeling stress-induced proteinopathies in Caenorhabditis elegans Elena Caldero-Escudero and Silvia Romero-Sanz Intravital imaging of mouse subcutaneous tumors placed in the ear for the study of immune cell interaction with blood vessels Almudena Manzanal, Beatrice Pinci, Carlos Luri-Rey, Diana Alcobia, David Causapé, and Álvaro Teijiera Induction of allergic dermatitis with dinitrofluorobenzene in Yama mice Yusuke Yamada-Satchwell, Kyoko Yoshizaki, Masashi Sakurai, and Masahiro Morimoto

Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza”. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology.Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals:OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience. Jose Manuel Bravo-San Pedro is currently a researcher at the Department of Physiology of the Complutense University of Madrid thanks to a Ramon y Cajal contract grant. He got his Ph.D. in biochemistry, cellular biology and genetics from the University of Extremadura (Caceres, Spain) in 2011, and he did a post-doctoral stage in the laboratory of Prof. Guido Kroemer. His main research interests have always been linked to autophagy, addressing this cellular process associated with neurodegenerative diseases or cancer and recently obesity and specifically related to problems in the correct functioning of the cilium. He is co-inventor of two patents and co-author of 110 publications indexed in PubMed in prestigious international journals, with h-index 45 and 23768 cites (Dec 2022). Fernando Aranda holds a BSc in Biology (2006) and Biochemistry (2007) from the University of Navarra. Then, he specialized in different strategies of Cancer Immunotherapy with a MSc in Biomedical Research (2008), and a PhD Degree (2012) from the University of Navarra (Pamplona) – Cima University of Navarra. More than 12 years in translational research focus on antitumor immune responses and Cancer Immunotherapy. Author of 64 publications indexed in PubMed in prestigious international journals, with h-index 30 and 4,296 cites (October 2022). He completed the Program of Sara Borrell (ISCIII) -competitive Postdoctoral contract- in the Group of Immune Receptors of the Innate and Adaptive System (IDIBAPS), Barcelona (2016-2018). Co-author of 1 invention patent: Composition based on the fibronectin domain A for the treatment of melanoma - WO/2011/101332. In 2012, Fernando Aranda obtained a Scientific Award, "Profesor Durantez" II Edición, for the best scientific article in Tumor Immunology by Fundación LAIR. Recently, Fernando Aranda awarded a competitive Research Fellow contract “Miguel Servet tipo I” by Instituto de Salud Carlos III, to continue his independent researcher career (IP) in cancer immunotherapy issues. Specifically, he is involved in Translational Immunotherapy of Peritoneal Carcinomatosis. Currently, Fernando Aranda leads a research group in cooperation with Dr. Pedro Berraondo.

• 1. Establishment single lung tumors through orthotopic injection Beñat Picabea, Céline Clémenson, Mirari Echepare, Cristina Viu-Idocin, Ane Álava, Estefanía Rodríguez, Michele Mondini, Karmele Valencia 2. Intracardiac injection as a metastatic model in lung cancerEstablishment single lung tumors through orthotopic injection Mirari Echepare, Beñat Picabea, Cristina Viu-Idocin, Ane Álava, Estefanía Rodríguez, Karmele Valencia 3. Adeno-associated viral vector administration to the inner ear and phenotype evaluation in a mouse model of hearing loss Sergio Isola and Carmen Unzu 4. DiLiCre2.0 mouse model: An advanced genome-editing tool to induce mutagenesis in vivo with high spatio-temporal resolution Miguel Vizosoa 5. A new inducible mouse model of FH loss Vincent Zecchini, Chrysanthi Moschandrea, Farina Schneider, and Christian Frezza 6. Monitoring neuronal mitophagy and locomotion deficits in a C. elegans model of Alzheimer's disease Giorgos Garcia Niforos, Eleni Tsakiri, and Konstantinos Palikaras 7. Experimental models and methods for infected wound modeling with Staphylococcus aureus Estela Pérez, Guillermo Landa, Isabel Bescós, Ignacio Ochoa, and Elena Tapia 8. Multiplex immunohistochemistry (IHC) profiling of murine tumour-infiltrating T cells Erminia Romano, Caron Behan, Alexander Baker, Garry Ashton, and Jamie Honeychurch 9. Isolation of Regulatory T Cells from Healthy Murine Mammary Glands D.Michael Mann, Hossein Ehsanbakhsh, and Paula D. Bos 10. Metastasis mouse model of breast cancer derived from Circulating Tumor Cells (CTCs) after primary orthotopic tumor resection. Angela Pérez-Cervera, Haritz Moreno, Helena Villanueva, Angelina Zheleva, Beatriz Moreno, Fernando Lecanda, Fernando Pastor 11. Establishment of humanized patient-derived xenografts (PDXs) from primary human colorectal cancer tumors Carmen Navarrete-Sirvent, Aurora Rivas-Crespo, María Teresa Sánchez-Montero, Alejandra Díaz-Chacón, Regina Peña-Enríquez, Enrique Aranda, Antonio Rodríguez-Ariza, and Silvia Guil-Luna Modeling stress-induced proteinopathies in Caenorhabditis elegans Elena Caldero-Escudero and Silvia Romero-Sanz Intravital imaging of mouse subcutaneous tumors placed in the ear for the study of immune cell interaction with blood vessels Almudena Manzanal, Beatrice Pinci, Carlos Luri-Rey, Diana Alcobia, David Causapé, and Álvaro Teijiera Induction of allergic dermatitis with dinitrofluorobenzene in Yama mice Yusuke Yamada-Satchwell, Kyoko Yoshizaki, Masashi Sakurai, and Masahiro Morimoto